Loading...
Market
Annual sales increase for semaglutide post-FLOW trial by end of 2025
5
Resolution / Starting Odds
Less than 10% increase • 25%
10% to 20% increase • 25%
20% to 30% increase • 25%
More than 30% increase • 25%
Annual financial reports from the manufacturing company
Story
FLOW Trial: Semaglutide 1.0mg Reduces Kidney, Cardiovascular Risks by 24% in Diabetic CKD Patients
May 24, 2024, 10:35 AM
The FLOW trial has shown that semaglutide, a GLP-1 receptor agonist, significantly reduces the risk of serious kidney outcomes, major cardiovascular events, and death among patients with type 2 diabetes and chronic kidney disease (CKD). The trial, which involved 3,533 participants over approximately three years, was stopped early due to its efficacy. Results indicated a 24% reduction in kidney disease progression and cardiovascular and kidney death. The study, published in NEJM, highlighted that a weekly 1.0mg dose of semaglutide was effective.
View original story
Similar markets
Positive results • 33%
Neutral results • 34%
Negative results • 33%
Increase by over 50% • 25%
Increase by 20-50% • 25%
Increase by less than 20% • 25%
Decrease • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30%+ • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Significant stock price increase (>15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (<5%) • 25%
Stock price decrease • 25%
Significant stock price increase (over 15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (0-5%) • 25%
Stock price decrease • 25%
Increase below 20% • 25%
20% to 40% increase • 25%
40% to 60% increase • 25%
Above 60% increase • 25%
Below £500 million • 25%
£500 million to £1 billion • 25%
£1 billion to £2 billion • 25%
Above £2 billion • 25%
Increase by less than 5% • 25%
Increase by 5% to 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Less than $500 million • 33%
$500 million - $1 billion • 33%
More than $1 billion • 34%
Less than $1 billion • 33%
$1-2 billion • 33%
More than $2 billion • 33%